Equities

Race Oncology Ltd

Race Oncology Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)1.37
  • Today's Change-0.02 / -1.44%
  • Shares traded98.70k
  • 1 Year change-28.46%
  • Beta1.5286
Data delayed at least 20 minutes, as of Apr 19 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.

  • Revenue in AUD (TTM)885.59k
  • Net income in AUD-11.17m
  • Incorporated2011
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arovella Therapeutics Ltd139.02k-10.23m120.77m14.00--33.39--868.71-0.0127-0.01270.00020.00340.0249--15.15---182.82-77.12-276.07-93.2683.5663.41-7,357.19-1,471.57----0.00--45.470.3491-18.11---68.72--
PharmAust Limited1.85m-7.79m126.19m52.00--16.04--68.17-0.0236-0.02010.00550.020.1977--6.71---83.26-25.56-96.46-28.7820.0690.73-421.04-59.16---104.650.00---13.533.42-263.63---47.47--
Vita Life Sciences Limited74.16m9.08m134.34m124.0014.523.1314.011.810.1660.1661.360.76951.332.347.35--16.2715.2522.5121.9958.1460.9012.2411.712.29--0.008939.0510.8812.5028.1830.0712.1519.14
Next Science Ltd34.47m-25.29m137.10m----6.88--3.98-0.1093-0.10930.14730.06831.467.478.33---107.19-74.40-136.06-90.3173.2076.98-73.36-128.263.45-50.370.0698--89.3650.80-28.29---2.28--
Proteomics International LaboratoriesLtd1.44m-5.90m146.60m----25.60--101.46-0.0518-0.05180.01290.04370.1817--11.13---75.75-57.79-87.11-67.57-----416.78-229.69---283.470.0088---14.644.12-24.20--89.02--
Dimerix Ltd181.28k-10.87m159.38m0.00--71.98--879.20-0.0294-0.02940.00050.0040.0169--0.7586---101.36-70.77-128.88-110.81-----5,994.52-61,882.73----0.4541--1,452.3212.76-31.57---8.26--
Cogstate Ltd64.53m8.57m222.85m61.0028.343.7817.353.450.04590.04590.34970.34420.7757--5.58--10.306.0113.849.2254.6951.5013.287.26----0.01350.00-8.627.25-52.56---5.06--
Race Oncology Ltd885.59k-11.17m230.41m----11.12--260.18-0.069-0.0690.00550.1250.0336--0.326---42.44-43.50-43.67-45.25-----1,261.86-5,058.82----0.00--997.6393.7811.41------
Probiotec Ltd221.22m8.69m231.77m111.0027.452.629.681.050.10380.10382.641.090.94837.036.99--3.724.585.365.9429.9530.213.935.731.093.330.493747.9017.3923.10-19.6120.8412.9718.77
Data as of Apr 19 2024. Currency figures normalised to Race Oncology Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.